Diabetes, bone, pain drugs may face German price cuts

by admin on April 18, 2013

FRANKFURT (Reuters) – Drugs from Novo Nordisk, Amgen, Bayer and other companies could face price cuts in Germany as the country's medical cost-benefit agency widens a review into the value offered by medicines. The Federal Joint Committee, or G-BA, said on Thursday it would review the cost-effectiveness of a range of drugs in different treatment areas. The list includes Novo's diabetes drug …

View full post on pain – Yahoo! News Search Results

Previous post:

Next post: